Literature DB >> 2886834

Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs.

J Poirier, M Roy, G Campanella, T Cloutier, S Paris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2886834     DOI： 10.1016/s0140-6736(87)92396-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease.

Authors:  O Gudjonsson; E Sanz; G Alván; S M Aquilonius; J Reviriego
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

3.  Acetylator polymorphism in Parkinson's disease.

Authors:  J M Ladero; F J Jimenez; J Benitez; M J Fernandez-Gundin; C Martinez; A Llerena; J Cobaleda; J J Muñoz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.